Melatonin Side Effects

Reported Melatonin side effects

Melatonin has an exceptionally wide safety margin and has been used in clinical doses up to 300mg/day in oncology protocols without serious acute toxicity. However, side effects are common at supraphysiological doses (3mg and above) and are often misattributed to insomnia or unrelated causes: Morning grogginess (drowsiness, "hangover," brain fog) is the most common complaint and is predominantly dose-related. Supraphysiological plasma levels (from 3-10mg doses) that persist into morning hours produce residual sedation, reduced morning alertness, delayed peak cognitive performance, and sometimes subjective depressive or flat mood. This is largely eliminated by dropping to 0.3-1mg, using immediate-release rather than extended-release formulations for most users, and timing the dose at least 30 minutes before intended sleep (not during the night if wakeful). Vivid dreams and nightmares are reported by 10-20% of users at 3-10mg doses, reflecting increased REM sleep pressure and altered REM architecture at high doses. Some users find the dream intensification positive; others find it disruptive. Nightmare frequency typically resolves within 2-3 weeks of continued use or with dose reduction to 0.3-1mg. Paradoxical insomnia and fragmented sleep occur in a minority of users and appear related to individual differences in receptor sensitivity, metabolism, and timing. Some individuals wake repeatedly after taking melatonin, particularly at higher doses; for these users, lower dose (0.3-0.5mg), earlier timing (4-5 hours before bed), or discontinuation is appropriate. Paradoxical insomnia is particularly reported in individuals with anxiety-spectrum disorders. Headache is reported in 5-10% of users, typically mild and self-limited, more common at higher doses. Mood effects: most users report neutral or mildly positive mood effects from appropriately-dosed evening melatonin. However, a minority report lowered mood, increased fatigue, or depression-like symptoms at high doses (particularly 5-10mg), which may reflect melatonin's interaction with the serotonin system and/or disruption of dopamine signaling in susceptible individuals. Users with histories of major depression should approach melatonin cautiously and discontinue if mood worsens; seasonal-affective-spectrum individuals may be particularly sensitive. Gastrointestinal effects (nausea, abdominal discomfort, diarrhea) are uncommon but reported, typically at higher doses. Modest hypothermia: evening melatonin produces a small drop in core body temperature (0.2-0.4°C), which is physiological and usually unnoticed but can be bothersome for some users. Hormonal effects: melatonin interacts with reproductive-axis hormones (suppresses LH in some contexts), growth hormone secretion (modest effects), and cortisol rhythm. These are usually subclinical but may be relevant in fertility planning, pregnancy, and hormone-sensitive conditions. Melatonin is a natural reproductive signal in seasonal breeders and long-term high-dose use theoretically could affect human reproductive physiology; the evidence is limited but supports caution in pregnancy, lactation, and fertility-seeking cycles. Drug interactions: The most clinically significant interaction is with fluvoxamine and other potent CYP1A2 inhibitors (ciprofloxacin, some antipsychotics), which can elevate melatonin exposure 17-23 fold — combining melatonin with fluvoxamine produces supraphysiological concentrations even from nominal 1mg doses. Warfarin metabolism may be affected (isolated reports of INR changes); patients on warfarin should monitor INR if starting melatonin. Benzodiazepines and Z-drugs combine additively with melatonin for sedation, generally safe but may produce unexpected morning sedation. Antihypertensives: melatonin's modest blood pressure-lowering effect may combine additively; monitor BP when starting melatonin in treated hypertension. Oral contraceptives: estrogen component inhibits CYP1A2, modestly raising melatonin exposure; usually not clinically significant. Immunosuppressants: theoretical concern that melatonin's immunomodulatory effects could interact with cyclosporine, tacrolimus, or other immunosuppressants; discuss with transplant or rheumatology team. Nifedipine effect may be reduced by melatonin in some studies. SSRIs and tricyclic antidepressants: generally compatible but monitor for excessive sedation or paradoxical stimulation. Pediatric safety: extensive pediatric use over the past two decades, particularly for ASD/ADHD-related sleep disorders, has revealed a generally favorable pediatric safety profile. However, concerns about long-term effects on pubertal development remain based on animal data suggesting melatonin modulates reproductive-axis hormones. Pediatric use is considered appropriate by many pediatricians when sleep problems are significant and behavioral measures have failed, at doses of 0.5-5mg under guidance, with periodic reassessment. Long-term pediatric safety data beyond 5-10 years is limited. Overdose: even very high single doses (up to 300mg) have not produced serious toxicity in documented cases. Accidental pediatric ingestions of adult supplement doses (10-20mg) typically produce only increased drowsiness and GI upset, managed supportively. The practical implication: melatonin has an extraordinarily wide therapeutic window compared to traditional sedatives. Long-term safety: while short-term studies are generally reassuring, long-term daily use beyond 1-2 years has limited controlled study in adults and particularly in pediatric populations. Theoretical concerns about pituitary-gonadal axis effects, receptor desensitization, and unknown long-term circadian consequences warrant periodic drug holidays or re-evaluation of ongoing need. Most sleep specialists recommend using melatonin as a time-limited intervention (jet lag, phase-shift correction, bridging to better sleep habits) rather than indefinite nightly use.

When to continue, reduce, or stop Melatonin

Melatonin contraindications

Melatonin has few absolute contraindications but multiple relative contraindications, interactions, and special-population considerations warranting caution. Relative contraindications warranting specific caution: Pregnancy and lactation: insufficient safety data for routine use. Melatonin crosses the placenta and appears in breast milk; endogenous maternal melatonin plays roles in fetal circadian entrainment, and supraphysiological exogenous exposure is of unclear safety. Some IVF protocols use melatonin for oocyte quality under reproductive endocrinology supervision, but this is an exception. Women planning pregnancy, pregnant, or lactating should discontinue melatonin unless specifically directed otherwise by their physician. Children under 4 years: not recommended outside specific physician-directed indications. Between ages 4-18, use is increasingly common for ASD/ADHD-related sleep disorders under pediatrician guidance, with doses typically 0.5-5mg and regular reassessment. Long-term effects on pubertal development remain theoretical concern without conclusive pediatric data beyond 5-10 years of use. Autoimmune diseases (rheumatoid arthritis, lupus, multiple sclerosis, Crohn's, autoimmune thyroid disease): theoretical concern that melatonin's immunostimulant effects on Th1 pathways could exacerbate autoimmune activity. Evidence is limited and mixed — some studies suggest benefit in specific autoimmune conditions, others suggest caution. Discuss with rheumatologist or immunologist before initiating, particularly in active disease phases or during immunosuppressive therapy adjustments. Hormone-sensitive conditions: melatonin modulates HPG-axis hormones, suppresses LH in some contexts, and has complex interactions with estrogen and androgen signaling. Patients with hormone-sensitive cancers (breast, prostate, endometrial, ovarian) should discuss with oncology team — melatonin may be beneficial as adjunct in some protocols but inappropriate in others. Endometriosis, severe PCOS, and menstrual-cycle abnormalities warrant reproductive endocrinology consultation. Bipolar disorder: rare reports of melatonin triggering or worsening mood episodes (particularly depressive or mixed states). Patients with bipolar disorder or family history should use melatonin cautiously and discontinue if mood changes occur. Seizure disorders: mixed evidence. Some animal and human data suggest melatonin has anticonvulsant properties; other reports have documented seizure threshold reduction in susceptible patients. Epilepsy patients should discuss with neurology before initiating. Diabetes: melatonin affects glucose metabolism in complex ways — large evening doses can blunt morning glucose regulation in some individuals. Type 2 diabetes patients starting melatonin should monitor morning glucose; dose adjustments of diabetes medications may be warranted. Hypertension on antihypertensive therapy: melatonin produces modest blood pressure reduction; combining with antihypertensives may produce additive effect. Monitor BP when starting melatonin. Active transplant recipients: immunosuppressant drug interactions (cyclosporine, tacrolimus, mTOR inhibitors) — discuss with transplant team. Renal impairment (CKD stages 3-5): melatonin is largely hepatically cleared, but accumulation of metabolites in severe renal disease is possible; dose reduction may be prudent in stage 4-5 CKD. Liver disease: melatonin is extensively metabolized by hepatic CYP1A2 and CYP2C19. Cirrhosis, severe hepatic dysfunction, or active hepatitis may reduce clearance substantially; start at lowest doses (0.3mg) and titrate cautiously. Major surgery (within 24 hours): discontinue melatonin 24 hours before major surgery given theoretical concerns about bleeding, sedation interaction with anesthesia, and immune modulation. Resume post-operatively per surgeon guidance. Drug interactions warranting attention: Fluvoxamine (Luvox) and other strong CYP1A2 inhibitors (ciprofloxacin, some quinolones, rofecoxib): can increase melatonin AUC 17-23 fold. This is clinically significant — combining fluvoxamine with even 1mg melatonin produces plasma levels equivalent to 17-23mg, with persistent next-day sedation. Dose reduction or alternative sleep approach warranted. Warfarin: case reports of INR elevation with melatonin initiation. Monitor INR in the 2-4 weeks after starting or changing melatonin dose. Benzodiazepines, Z-drugs, sedating antihistamines: additive sedation, generally safe but potential for unexpected morning grogginess. Consider dose reduction of one or both. Alcohol: disrupts sleep architecture; combining with melatonin doesn't prevent alcohol's sleep fragmentation. Minimize alcohol use in individuals managing sleep issues with melatonin. Immunosuppressants: theoretical interaction; discuss with prescribing specialist. Oral contraceptives: estrogen inhibits CYP1A2 modestly, raising melatonin exposure; usually not clinically significant. Caffeine: antagonizes adenosine-mediated sleep pressure and delays endogenous melatonin onset; maintain afternoon caffeine cutoff. Nifedipine: some evidence of reduced nifedipine effect with melatonin; monitor BP. SSRIs, SNRIs, tricyclics: generally compatible; theoretical serotonin pathway considerations rarely clinically significant. Monitor for excessive sedation or paradoxical stimulation. MAOIs: theoretical interaction; caution recommended given MAOI's overall tight dietary and drug interaction restrictions. Tamoxifen and aromatase inhibitors: melatonin-estrogen interactions complex; oncology team supervision essential. Absolute contraindications: none in the strict sense. However, melatonin should not be used in: Known hypersensitivity to melatonin or product excipients Active fluvoxamine therapy without dose adjustment Pregnancy without specific physician direction Children under 2 years (except rare physician-directed specialized indications) When to stop melatonin and seek medical evaluation: Persistent insomnia despite 4 weeks of appropriate melatonin use (consider sleep study, evaluation for sleep apnea, RLS, depression, or chronobiotic disorder) Development of daytime sedation, cognitive impairment, or mood decline Paradoxical worsening of sleep New or worsening depression or anxiety symptoms Development of vivid nightmares that don't resolve with dose reduction Unexpected morning or daytime sedation suggesting drug interaction Development of jaundice, persistent GI symptoms, or unusual bleeding/bruising Pregnancy or pregnancy planning Any major new medication addition warranting interaction review This is general educational content, not individualized medical advice. Individuals with chronic sleep difficulties, medical conditions, or on multiple medications should consult their physician before initiating melatonin. Melatonin is a hormone with metabolic, reproductive, immune, and chronobiotic effects, and its long-term use warrants periodic clinical reassessment rather than indefinite unsupervised use.

Why vendor quality drives Melatonin side-effect frequency

Research-compound communities consistently report that adverse-event frequency tracks with source quality. Three reasons: (1) impurity profiles vary by lab (residual synthesis byproducts can trigger reactions); (2) mislabeled mass means actual dose can be 50-150% of stated dose; (3) reconstitution-grade water and capping methodology affect long-term storage stability. COA-verified vendors with published HPLC data minimize all three failure modes. Check a vendor's COA record and Trust Score before you buy.

Melatonin side effects FAQ

Research-use disclaimer. All safety information on this page summarizes published research literature and community-reported reactions. It is not medical advice and not authorization for human consumption. Always consult a licensed practitioner before any compound enters a clinical context. Compounds linked from this page are sold for research-use only.
Affiliate disclosure. See our affiliate disclosure .